1
40
2
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1002/jmri.27731">http://doi.org/10.1002/jmri.27731</a></td>
</tr></tbody></table>
Pages
1660-1675
Issue
5
Volume
54
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Radiology
Update Year & Number
Jan to Aug list 2021
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.
Creator
An entity primarily responsible for making the resource
DeLano MC; Spampinato MV; Chang EY; Barr RG; Lichtenstein RJ; Colosimo C; Vymazal J; Wen Z; Lin DDM; Kirchin MA; Pirovano G
Publisher
An entity responsible for making the resource available
Journal Of Magnetic Resonance Imaging : JMRI
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-05-20
Description
An account of the resource
Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols.
Subject
The topic of the resource
To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS).
Identifier
An unambiguous reference to the resource within a given context
<table width="91" style="border-collapse:collapse;width:68pt;"><colgroup><col width="91" style="width:68pt;" /></colgroup><tbody><tr style="height:15pt;"><td width="91" height="20" class="xl18" style="width:68pt;height:15pt;"><a href="http://doi.org/10.1002/jmri.27731">http://doi.org/10.1002/jmri.27731</a></td>
</tr></tbody></table>
Format
The file format, physical medium, or dimensions of the resource
Journal Article
2021
Comparative Studies
contrast efficacy
gadobenate dimeglumine
GBCA safety
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">http://doi.org/10.1002/jmri.27731</a>
ISSN
1522-2586 1053-1807
Search for Full-text
Locate full-text within NEOMED Library's e-journal collections
<a href="http://neomed.idm.oclc.org/login?url=http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">NEOMED Full-text Holding (if available) - Proxy DOI: 10.1002/jmri.27731</a>
<p>Users with a NEOMED Library login can search for full-text journal articles at the following url: <a href="https://libraryguides.neomed.edu/home">https://libraryguides.neomed.edu/home</a></p>
Update Year & Number
June 2021 List
NEOMED College
NEOMED College of Medicine
NEOMED Department
Department of Radiology
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Dose-Lowering in Contrast-Enhanced MRI of the Central Nervous System: A Retrospective, Parallel-Group Comparison Using Gadobenate Dimeglumine.
Publisher
An entity responsible for making the resource available
Journal Of Magnetic Resonance Imaging : JMRI
Date
A point or period of time associated with an event in the lifecycle of the resource
2021
2021-05-20
Subject
The topic of the resource
comparative studies; contrast efficacy; gadobenate dimeglumine; GBCA safety
Creator
An entity primarily responsible for making the resource
DeLano MC; Spampinato MV; Chang EY; Barr RG; Lichtenstein RJ; Colosimo C; Vymazal J; Wen Z; Lin DDM; Kirchin MA; Pirovano G
Description
An account of the resource
BACKGROUND: Concerns over gadolinium (Gd) retention encourage the use of lower Gd doses. However, lower Gd doses may compromise imaging performance. Higher relaxivity gadobenate may be suited to reduced dose protocols. PURPOSE: To compare 0.05 mmol/kg and 0.1 mmol/kg gadobenate in patients undergoing enhanced MRI of the central nervous system (CNS). STUDY TYPE: Retrospective, multicenter. POPULATION: Three hundred and fifty-two patients receiving 0.05 (n = 181) or 0.1 (n = 171) mmol/kg gadobenate. FIELD STRENGTH/SEQUENCES: 1.5 T and 3.0 T/precontrast and postcontrast T1-weighted spin echo/fast spin echo (SE/FSE) and/or gradient echo/fast field echo (GRE/FFE); precontrast T2-weighted FSE and T2-FLAIR. ASSESSMENT: Images of patients with extra-axial lesions at 1.5 T or any CNS lesion at 3.0 T were reviewed by three blinded, independent neuroradiologists for qualitative (lesion border delineation, internal morphology visualization, contrast enhancement; scores from 1 = poor to 4 = excellent) and quantitative (lesion-to-brain ratio [LBR], contrast-to-noise ratio [CNR]; SI measurements at regions-of-interest on lesion and normal parenchyma) enhancement measures. Noninferiority of 0.05 mmol/kg gadobenate was determined for each qualitative endpoint if the lower limit of the 95% confidence interval (CI) for the difference in precontrast + postcontrast means was above a noninferiority margin of -0.4. STATISTICAL TESTS: Student's t-test for comparison of mean qualitative endpoint scores, Wilcoxon signed rank test for comparison of LBR and CNR values; Wilcoxon rank sum test for comparison of SI changes. Tests were significant for P < 0.05. RESULTS: The mean change from precontrast to precontrast + postcontrast was significant for all endpoints. Readers 1, 2, and 3 evaluated 304, 225, and 249 lesions for 0.05 mmol/kg gadobenate, and 382, 309, and 298 lesions for 0.1 mmol/kg gadobenate. The lower limit of the 95% CI was above -0.4 for all comparisons. Significantly, higher LBR and CNR was observed with the higher dose. DATA CONCLUSION: 0.05 mmol/kg gadobenate was noninferior to 0.1 mmol/kg gadobenate for lesion visualization. EVIDENCE LEVEL: 2 TECHNICAL EFFICACY: Stage 3.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1002/jmri.27731" target="_blank" rel="noreferrer noopener">10.1002/jmri.27731</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
Format
The file format, physical medium, or dimensions of the resource
journalArticle
2021
Barr RG
Chang EY
Colosimo C
Comparative Studies
contrast efficacy
DeLano MC
Department of Radiology
gadobenate dimeglumine
GBCA safety
Journal of magnetic resonance imaging : JMRI
journalArticle
June 2021 List
Kirchin MA
Lichtenstein RJ
Lin DDM
NEOMED College of Medicine
Pirovano G
Spampinato MV
Vymazal J
Wen Z